Literature DB >> 22007939

Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans.

Matteo Landriscina1, Giuseppe Pannone, Annamaria Piscazzi, Paolo Toti, Annarita Fabiano, Simona Tortorella, Rossella Occhini, Antonio Ambrosi, Pantaleo Bufo, Mauro Cignarelli.   

Abstract

BACKGROUND: Epidermal growth factor receptor 1 (EGFR1) signaling is involved in human cancer cell progression and is responsible for aggressive biological behavior and poor clinical outcome in several human malignancies. Activation of the EGFR1 pathway has been proposed, among others, as being involved in the progression of thyroid cancer toward a thyroid-stimulating hormone (TSH)-independent phenotype. We have previously observed that undifferentiated thyroid carcinoma cells are hyper-sensitive to EGF signaling of downstream intracellular pathways, and this correlated both with the loss of TSH-dependency and increase in EGF-dependent proliferation and migration. Thus, we hypothesized that the upregulation of EGFR1 protein expression may be enhanced in parallel with transition toward a poorly differentiated phenotype in human thyroid carcinomas.
METHODS: The expression of EGFR1 was evaluated, by immunohistochemistry, in a series of 49 human thyroid carcinomas at different degrees of tumor differentiation.
RESULTS: The expression of EGFR1 protein was significantly upregulated in poorly differentiated and anaplastic thyroid carcinomas, whereas it was absent or faint in normal thyroid gland tissue and in differentiated thyroid papillary carcinomas. Of note, selected thyroid tumors characterized by a mixed population of differentiated and undifferentiated tumor cells, likely progressing from well to poorly differentiated and anaplastic phenotypes, exhibited EGFR1-negative differentiated fields together with EGFR1-positive poorly differentiated and anaplastic areas.
CONCLUSIONS: Upregulation of EGFR1 expression may be a molecular marker of dedifferentiation in thyroid epithelial carcinomas, likely being responsible for the activation of EGF signaling observed in tumor cells and favoring progression toward an angiogenic, poorly differentiated, TSH-independent phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007939     DOI: 10.1089/thy.2011.0172

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

1.  Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.

Authors:  Sonja Šelemetjev; Aleksandar Bartolome; Tijana Išić Denčić; Ilona Đorić; Ivan Paunović; Svetislav Tatić; Dubravka Cvejić
Journal:  Int J Exp Pathol       Date:  2018-04-17       Impact factor: 1.925

2.  Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Authors:  Kevin E Fisher; Jigna C Jani; Sarah B Fisher; Cora Foulks; Charles E Hill; Collin J Weber; Cynthia Cohen; Jyotirmay Sharma
Journal:  J Surg Res       Date:  2013-05-23       Impact factor: 2.192

3.  The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression.

Authors:  Heather Hardin; Zhenying Guo; Weihua Shan; Celina Montemayor-Garcia; Sofia Asioli; Xiao-Min Yu; April D Harrison; Herbert Chen; Ricardo V Lloyd
Journal:  Am J Pathol       Date:  2014-06-17       Impact factor: 4.307

Review 4.  Selective use of vandetanib in the treatment of thyroid cancer.

Authors:  Poupak Fallahi; Flavia Di Bari; Silvia Martina Ferrari; Roberto Spisni; Gabriele Materazzi; Paolo Miccoli; Salvatore Benvenga; Alessandro Antonelli
Journal:  Drug Des Devel Ther       Date:  2015-07-03       Impact factor: 4.162

5.  Zn(II)-curc targets p53 in thyroid cancer cells.

Authors:  Alessia Garufi; Valerio D'Orazi; Alessandra Crispini; Gabriella D'Orazi
Journal:  Int J Oncol       Date:  2015-08-13       Impact factor: 5.650

Review 6.  New therapies for dedifferentiated papillary thyroid cancer.

Authors:  Poupak Fallahi; Valeria Mazzi; Roberto Vita; Silvia Martina Ferrari; Gabriele Materazzi; David Galleri; Salvatore Benvenga; Paolo Miccoli; Alessandro Antonelli
Journal:  Int J Mol Sci       Date:  2015-03-17       Impact factor: 5.923

7.  Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.

Authors:  Huairong Zhang; Bo Gao; Bingyin Shi
Journal:  Dis Markers       Date:  2016-09-15       Impact factor: 3.434

8.  Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer.

Authors:  Seo Yun Kim; Hye-Ryoun Kim; Cheol Hyeon Kim; Jae Soo Koh; Hee Jong Baek; Chang-Min Choi; Joon Seon Song; Jae Cheol Lee; Im Ii Na
Journal:  Ann Thorac Med       Date:  2017 Jan-Mar       Impact factor: 2.219

9.  Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population.

Authors:  Hye Sook Min; Chul Lee; Kyeong Cheon Jung
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

Review 10.  Molecular Targeted Therapies of Aggressive Thyroid Cancer.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ugo Politti; Gabriele Materazzi; Enke Baldini; Salvatore Ulisse; Paolo Miccoli; Alessandro Antonelli
Journal:  Front Endocrinol (Lausanne)       Date:  2015-11-20       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.